335 related articles for article (PubMed ID: 26316561)
1. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
Sandrock CE; Shorr AF
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S79-86. PubMed ID: 26316561
[TBL] [Abstract][Full Text] [Related]
2. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.
Barriere SL
Future Microbiol; 2014; 9(3):281-9. PubMed ID: 24450506
[TBL] [Abstract][Full Text] [Related]
3. Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.
Liapikou A; Dimakou K; Toumbis M
Ther Adv Respir Dis; 2016 Aug; 10(4):368-78. PubMed ID: 27340253
[TBL] [Abstract][Full Text] [Related]
4. Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.
Nannini EC; Corey GR; Stryjewski ME
Expert Rev Anti Infect Ther; 2012 Aug; 10(8):847-54. PubMed ID: 23030322
[TBL] [Abstract][Full Text] [Related]
5. The clinical positioning of telavancin in Europe.
Masterton R; Cornaglia G; Courvalin P; Lode HM; Rello J; Torres A
Int J Antimicrob Agents; 2015 Mar; 45(3):213-20. PubMed ID: 25600892
[TBL] [Abstract][Full Text] [Related]
6. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
Corey GR; Rubinstein E; Stryjewski ME; Bassetti M; Barriere SL
Clin Infect Dis; 2015 Mar; 60(5):787-96. PubMed ID: 25472944
[TBL] [Abstract][Full Text] [Related]
7. Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.
Lacy MK; Stryjewski ME; Wang W; Hardin TC; Nogid B; Luke DR; Shorr AF; Corey GR; Barriere SL
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S87-93. PubMed ID: 26316562
[TBL] [Abstract][Full Text] [Related]
8. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
Karlowsky JA; Nichol K; Zhanel GG
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559
[TBL] [Abstract][Full Text] [Related]
9. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
Rubinstein E; Lalani T; Corey GR; Kanafani ZA; Nannini EC; Rocha MG; Rahav G; Niederman MS; Kollef MH; Shorr AF; Lee PC; Lentnek AL; Luna CM; Fagon JY; Torres A; Kitt MM; Genter FC; Barriere SL; Friedland HD; Stryjewski ME;
Clin Infect Dis; 2011 Jan; 52(1):31-40. PubMed ID: 21148517
[TBL] [Abstract][Full Text] [Related]
10. The role of telavancin in the treatment of MRSA infections in hospital.
Bassetti M; Mikulska M; Righi E; Nicolini L; Viscoli C
Expert Opin Investig Drugs; 2009 Apr; 18(4):521-9. PubMed ID: 19335280
[TBL] [Abstract][Full Text] [Related]
11. Telavancin: a review of its use in patients with nosocomial pneumonia.
Scott LJ
Drugs; 2013 Nov; 73(16):1829-39. PubMed ID: 24190596
[TBL] [Abstract][Full Text] [Related]
12. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.
Stryjewski ME; Lentnek A; O'Riordan W; Pullman J; Tambyah PA; MirĂ³ JM; Fowler VG; Barriere SL; Kitt MM; Corey GR
BMC Infect Dis; 2014 May; 14():289. PubMed ID: 24884578
[TBL] [Abstract][Full Text] [Related]
13. Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis.
Ruggero MA; Peaper DR; Topal JE
Infect Dis (Lond); 2015 Jun; 47(6):379-84. PubMed ID: 25746601
[TBL] [Abstract][Full Text] [Related]
14. Telavancin: a new lipoglycopeptide for gram-positive infections.
Smith WJ; Drew RH
Drugs Today (Barc); 2009 Mar; 45(3):159-73. PubMed ID: 19436839
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia.
Krause KM; Blais J; Lewis SR; Lunde CS; Barriere SL; Friedland HD; Kitt MM; Benton BM
Diagn Microbiol Infect Dis; 2012 Dec; 74(4):429-31. PubMed ID: 23083812
[TBL] [Abstract][Full Text] [Related]
16. Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.
Rubinstein E; Corey GR; Stryjewski ME; Kanafani ZA
Expert Opin Pharmacother; 2011 Dec; 12(17):2737-50. PubMed ID: 22077833
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.
Adamantia L; Antoni T
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):803-12. PubMed ID: 27158752
[TBL] [Abstract][Full Text] [Related]
18. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
Laohavaleeson S; Kuti JL; Nicolau DP
Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
[TBL] [Abstract][Full Text] [Related]
19. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia.
Haque NZ; Zuniga LC; Peyrani P; Reyes K; Lamerato L; Moore CL; Patel S; Allen M; Peterson E; Wiemken T; Cano E; Mangino JE; Kett DH; Ramirez JA; Zervos MJ;
Chest; 2010 Dec; 138(6):1356-62. PubMed ID: 20558550
[TBL] [Abstract][Full Text] [Related]
20. Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus.
McKinnell JA; Corman S; Patel D; Leung GH; Gordon LM; Lodise TP
Clin Ther; 2018 Mar; 40(3):406-414.e2. PubMed ID: 29454592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]